F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi
With infections caused by the fungal pathogen Candida auris spreading at an “alarming rate” in the US, according to the Centers for Disease Control and Prevention
An FDA advisory committee has recommended approval of Cidara Therapeutics' once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caus
With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from
The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho